+关注
ShawnHeng
暂无个人介绍
IP属地：未知
64
关注
3
粉丝
0
主题
0
勋章
主贴
热门
ShawnHeng
2021-08-04
Yeah! 👍
抱歉，原内容已删除
ShawnHeng
2021-07-30
[Cry]
抱歉，原内容已删除
ShawnHeng
2021-07-22
👍
抱歉，原内容已删除
ShawnHeng
2021-06-23
👍
Second Sight Medical Products Announces Pricing of Public Offering
去老虎APP查看更多动态
{"i18n":{"language":"zh_CN"},"userPageInfo":{"id":"3583646104988043","uuid":"3583646104988043","gmtCreate":1620552647364,"gmtModify":1624417530879,"name":"ShawnHeng","pinyin":"shawnheng","introduction":"","introductionEn":null,"signature":"","avatar":"https://static.tigerbbs.com/72e8cfcb05b06fcd153a93daf9b7196a","hat":null,"hatId":null,"hatName":null,"vip":1,"status":2,"fanSize":3,"headSize":64,"tweetSize":4,"questionSize":0,"limitLevel":999,"accountStatus":4,"level":{"id":1,"name":"萌萌虎","nameTw":"萌萌虎","represent":"呱呱坠地","factor":"评论帖子3次或发布1条主帖（非转发）","iconColor":"3C9E83","bgColor":"A2F1D9"},"themeCounts":0,"badgeCounts":0,"badges":[],"moderator":false,"superModerator":false,"manageSymbols":null,"badgeLevel":null,"boolIsFan":false,"boolIsHead":false,"favoriteSize":0,"symbols":null,"coverImage":null,"realNameVerified":null,"userBadges":[{"badgeId":"e50ce593bb40487ebfb542ca54f6a561-1","templateUuid":"e50ce593bb40487ebfb542ca54f6a561","name":"出道虎友","description":"加入老虎社区500天","bigImgUrl":"https://static.tigerbbs.com/0e4d0ca1da0456dc7894c946d44bf9ab","smallImgUrl":"https://static.tigerbbs.com/0f2f65e8ce4cfaae8db2bea9b127f58b","grayImgUrl":"https://static.tigerbbs.com/c5948a31b6edf154422335b265235809","redirectLinkEnabled":0,"redirectLink":null,"hasAllocated":1,"isWearing":0,"stamp":null,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2022.09.22","exceedPercentage":null,"individualDisplayEnabled":0,"backgroundColor":null,"fontColor":null,"individualDisplaySort":0,"categoryType":1001},{"badgeId":"518b5610c3e8410da5cfad115e4b0f5a-1","templateUuid":"518b5610c3e8410da5cfad115e4b0f5a","name":"实盘交易者","description":"完成一笔实盘交易","bigImgUrl":"https://static.tigerbbs.com/2e08a1cc2087a1de93402c2c290fa65b","smallImgUrl":"https://static.tigerbbs.com/4504a6397ce1137932d56e5f4ce27166","grayImgUrl":"https://static.tigerbbs.com/4b22c79415b4cd6e3d8ebc4a0fa32604","redirectLinkEnabled":0,"redirectLink":null,"hasAllocated":1,"isWearing":0,"stamp":null,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2021.12.21","exceedPercentage":null,"individualDisplayEnabled":0,"backgroundColor":null,"fontColor":null,"individualDisplaySort":0,"categoryType":1100}],"userBadgeCount":2,"currentWearingBadge":null,"individualDisplayBadges":null,"crmLevel":2,"crmLevelSwitch":0,"location":"未知","starInvestorFollowerNum":0,"starInvestorFlag":false,"starInvestorOrderShareNum":0,"subscribeStarInvestorNum":0,"ror":null,"winRationPercentage":null,"showRor":false,"investmentPhilosophy":null,"starInvestorSubscribeFlag":false},"baikeInfo":{},"tab":"post","tweets":[{"id":807499054,"gmtCreate":1628047638878,"gmtModify":1631891044179,"author":{"id":"3583646104988043","authorId":"3583646104988043","name":"ShawnHeng","avatar":"https://static.tigerbbs.com/72e8cfcb05b06fcd153a93daf9b7196a","crmLevel":2,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3583646104988043","authorIdStr":"3583646104988043"},"themes":[],"htmlText":"Yeah! 👍","listText":"Yeah! 👍","text":"Yeah! 👍","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":8,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/807499054","repostId":"2156312793","repostType":4,"isVote":1,"tweetType":1,"viewCount":206,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":808705597,"gmtCreate":1627608897619,"gmtModify":1631891044184,"author":{"id":"3583646104988043","authorId":"3583646104988043","name":"ShawnHeng","avatar":"https://static.tigerbbs.com/72e8cfcb05b06fcd153a93daf9b7196a","crmLevel":2,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3583646104988043","authorIdStr":"3583646104988043"},"themes":[],"htmlText":"[Cry] ","listText":"[Cry] ","text":"[Cry]","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":1,"repostSize":0,"link":"https://laohu8.com/post/808705597","repostId":"1105519179","repostType":4,"isVote":1,"tweetType":1,"viewCount":169,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":176500112,"gmtCreate":1626904165436,"gmtModify":1631891044187,"author":{"id":"3583646104988043","authorId":"3583646104988043","name":"ShawnHeng","avatar":"https://static.tigerbbs.com/72e8cfcb05b06fcd153a93daf9b7196a","crmLevel":2,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3583646104988043","authorIdStr":"3583646104988043"},"themes":[],"htmlText":"👍","listText":"👍","text":"👍","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/176500112","repostId":"1183334651","repostType":2,"isVote":1,"tweetType":1,"viewCount":212,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":123803398,"gmtCreate":1624414132814,"gmtModify":1631891044190,"author":{"id":"3583646104988043","authorId":"3583646104988043","name":"ShawnHeng","avatar":"https://static.tigerbbs.com/72e8cfcb05b06fcd153a93daf9b7196a","crmLevel":2,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3583646104988043","authorIdStr":"3583646104988043"},"themes":[],"htmlText":"👍","listText":"👍","text":"👍","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":2,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/123803398","repostId":"2145061761","repostType":4,"repost":{"id":"2145061761","kind":"news","pubTimestamp":1624411200,"share":"https://www.laohu8.com/m/news/2145061761?lang=&edition=full","pubTime":"2021-06-23 09:20","market":"us","language":"en","title":"Second Sight Medical Products Announces Pricing of Public Offering","url":"https://stock-news.laohu8.com/highlight/detail?id=2145061761","media":"Business Wire","summary":"LOS ANGELES, June 23, 2021--(BUSINESS WIRE)--Second Sight Medical Products, Inc. (NASDAQ: EYES) (\"Se","content":"<p><b>LOS ANGELES, June 23, 2021</b>--(BUSINESS WIRE)--<a href=\"https://laohu8.com/S/EYES\">Second Sight Medical Products</a>, Inc. (NASDAQ: EYES) (\"Second Sight\" or the \"Company\"), a leading developer of implantable visual prosthetics that are intended to create an artificial form of useful vision for blind individuals, today announced the pricing of its underwritten public offering of 10,000,000 shares of its common stock at a public offering price of $5.00 per share, for gross proceeds of $50,000,000, before deducting underwriting discounts, commissions and other offering expenses. In addition, the Company has granted the underwriters a 45-day option to purchase up to an additional 1,500,000 shares of common stock, solely to cover over-allotments. All of the shares of common stock are being offered by the Company.</p>\n<p>The offering is expected to close on June 25, 2021, subject to satisfaction of customary closing conditions.</p>\n<p>ThinkEquity, a division of Fordham Financial Management, Inc., is acting as sole book-running manager for the offering.</p>\n<p>The Company intends to use the net proceeds from the offering primarily for development of the Orion device and general corporate purposes.</p>\n<p>The securities will be offered and sold pursuant to a shelf registration statement on Form S-3 (File No. 333-256904), including a base prospectus, filed with the U.S. Securities and Exchange Commission (the \"SEC\") on June 8, 2021 and declared effective on June 14, 2021. The offering will be made only by means of a written prospectus. A preliminary prospectus supplement and accompanying prospectus describing the terms of the offering has been filed with the SEC on its website at www.sec.gov. Copies of the preliminary prospectus supplement and the accompanying prospectus relating to the offering may also be obtained from the offices of ThinkEquity, a division of Fordham Financial Management, Inc., 17 State Street, 22nd Floor, New York, New York 10004, by telephone at (877) 436-3673 or by email at prospectus@think-equity.com. Before investing in this offering, interested parties should read in their entirety the preliminary prospectus supplement and the accompanying prospectus and the other documents that the Company has filed with the SEC that are incorporated by reference in such preliminary prospectus supplement and the accompanying prospectus, which provide more information about the Company and such offering.</p>\n<p>This press release shall not constitute an offer to sell or a solicitation of an offer to buy, nor shall there be any sale of these securities in any state or jurisdiction in which such an offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction.</p>\n<p><b>About the Orion Visual Cortical Prosthesis System</b></p>\n<p>Leveraging Second Sight’s 20 years of experience in neuromodulation for vision, the Orion Visual Cortical Prosthesis System (Orion) is an implanted cortical stimulation device intended to provide useful artificial vision to individuals who are blind due to a wide range of causes, including glaucoma, diabetic retinopathy, optic nerve injury or disease, and eye injury. Orion is intended to convert images captured by a miniature video camera mounted on glasses into a series of small electrical pulses. The device is designed to bypass diseased or injured eye anatomy and to transmit these electrical pulses wirelessly to an array of electrodes implanted on the surface of the brain’s visual cortex, where it is intended to provide the perception of patterns of light. A six-subject early feasibility study of the Orion is currently underway at the Ronald Reagan UCLA Medical Center in Los Angeles and the Baylor College of Medicine in Houston. No peer-reviewed data is available yet for the Orion system.</p>\n<p><b>About Second Sight Medical Products, Inc.</b></p>\n<p>Second Sight Medical Products, Inc. (Nasdaq: EYES) develops implantable visual prosthetics that are intended to deliver useful artificial vision to blind individuals. A recognized global leader in neuromodulation devices for blindness, the Company is committed to developing new technologies to treat the broadest population of sight-impaired individuals. The Company’s headquarters are in Los Angeles, California. More information is available at https://secondsight.com/.</p>","source":"yahoofinance","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Second Sight Medical Products Announces Pricing of Public Offering</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nSecond Sight Medical Products Announces Pricing of Public Offering\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-06-23 09:20 GMT+8 <a href=https://finance.yahoo.com/news/second-sight-medical-products-announces-005900674.html><strong>Business Wire</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>LOS ANGELES, June 23, 2021--(BUSINESS WIRE)--Second Sight Medical Products, Inc. (NASDAQ: EYES) (\"Second Sight\" or the \"Company\"), a leading developer of implantable visual prosthetics that are ...</p>\n\n<a href=\"https://finance.yahoo.com/news/second-sight-medical-products-announces-005900674.html\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{},"source_url":"https://finance.yahoo.com/news/second-sight-medical-products-announces-005900674.html","is_english":true,"share_image_url":"https://static.laohu8.com/5f26f4a48f9cb3e29be4d71d3ba8c038","article_id":"2145061761","content_text":"LOS ANGELES, June 23, 2021--(BUSINESS WIRE)--Second Sight Medical Products, Inc. (NASDAQ: EYES) (\"Second Sight\" or the \"Company\"), a leading developer of implantable visual prosthetics that are intended to create an artificial form of useful vision for blind individuals, today announced the pricing of its underwritten public offering of 10,000,000 shares of its common stock at a public offering price of $5.00 per share, for gross proceeds of $50,000,000, before deducting underwriting discounts, commissions and other offering expenses. In addition, the Company has granted the underwriters a 45-day option to purchase up to an additional 1,500,000 shares of common stock, solely to cover over-allotments. All of the shares of common stock are being offered by the Company.\nThe offering is expected to close on June 25, 2021, subject to satisfaction of customary closing conditions.\nThinkEquity, a division of Fordham Financial Management, Inc., is acting as sole book-running manager for the offering.\nThe Company intends to use the net proceeds from the offering primarily for development of the Orion device and general corporate purposes.\nThe securities will be offered and sold pursuant to a shelf registration statement on Form S-3 (File No. 333-256904), including a base prospectus, filed with the U.S. Securities and Exchange Commission (the \"SEC\") on June 8, 2021 and declared effective on June 14, 2021. The offering will be made only by means of a written prospectus. A preliminary prospectus supplement and accompanying prospectus describing the terms of the offering has been filed with the SEC on its website at www.sec.gov. Copies of the preliminary prospectus supplement and the accompanying prospectus relating to the offering may also be obtained from the offices of ThinkEquity, a division of Fordham Financial Management, Inc., 17 State Street, 22nd Floor, New York, New York 10004, by telephone at (877) 436-3673 or by email at prospectus@think-equity.com. Before investing in this offering, interested parties should read in their entirety the preliminary prospectus supplement and the accompanying prospectus and the other documents that the Company has filed with the SEC that are incorporated by reference in such preliminary prospectus supplement and the accompanying prospectus, which provide more information about the Company and such offering.\nThis press release shall not constitute an offer to sell or a solicitation of an offer to buy, nor shall there be any sale of these securities in any state or jurisdiction in which such an offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction.\nAbout the Orion Visual Cortical Prosthesis System\nLeveraging Second Sight’s 20 years of experience in neuromodulation for vision, the Orion Visual Cortical Prosthesis System (Orion) is an implanted cortical stimulation device intended to provide useful artificial vision to individuals who are blind due to a wide range of causes, including glaucoma, diabetic retinopathy, optic nerve injury or disease, and eye injury. Orion is intended to convert images captured by a miniature video camera mounted on glasses into a series of small electrical pulses. The device is designed to bypass diseased or injured eye anatomy and to transmit these electrical pulses wirelessly to an array of electrodes implanted on the surface of the brain’s visual cortex, where it is intended to provide the perception of patterns of light. A six-subject early feasibility study of the Orion is currently underway at the Ronald Reagan UCLA Medical Center in Los Angeles and the Baylor College of Medicine in Houston. No peer-reviewed data is available yet for the Orion system.\nAbout Second Sight Medical Products, Inc.\nSecond Sight Medical Products, Inc. (Nasdaq: EYES) develops implantable visual prosthetics that are intended to deliver useful artificial vision to blind individuals. A recognized global leader in neuromodulation devices for blindness, the Company is committed to developing new technologies to treat the broadest population of sight-impaired individuals. The Company’s headquarters are in Los Angeles, California. More information is available at https://secondsight.com/.","news_type":1},"isVote":1,"tweetType":1,"viewCount":325,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0}],"hots":[{"id":807499054,"gmtCreate":1628047638878,"gmtModify":1631891044179,"author":{"id":"3583646104988043","authorId":"3583646104988043","name":"ShawnHeng","avatar":"https://static.tigerbbs.com/72e8cfcb05b06fcd153a93daf9b7196a","crmLevel":2,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"3583646104988043","idStr":"3583646104988043"},"themes":[],"htmlText":"Yeah! 👍","listText":"Yeah! 👍","text":"Yeah! 👍","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":8,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/807499054","repostId":"2156312793","repostType":4,"isVote":1,"tweetType":1,"viewCount":206,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":808705597,"gmtCreate":1627608897619,"gmtModify":1631891044184,"author":{"id":"3583646104988043","authorId":"3583646104988043","name":"ShawnHeng","avatar":"https://static.tigerbbs.com/72e8cfcb05b06fcd153a93daf9b7196a","crmLevel":2,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"3583646104988043","idStr":"3583646104988043"},"themes":[],"htmlText":"[Cry] ","listText":"[Cry] ","text":"[Cry]","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":1,"repostSize":0,"link":"https://laohu8.com/post/808705597","repostId":"1105519179","repostType":4,"repost":{"id":"1105519179","kind":"news","pubTimestamp":1627599998,"share":"https://www.laohu8.com/m/news/1105519179?lang=&edition=full","pubTime":"2021-07-30 07:06","market":"us","language":"en","title":"Amazon sales growth slows in tame start to Jassy's tenure as CEO","url":"https://stock-news.laohu8.com/highlight/detail?id=1105519179","media":"Reuters","summary":" -Amazon.com Inc on Thursday said sales growth would decelerate in the third quarter as customers leave their homes more, a slow start to the reign of CEO Andy Jassy after 27 years with Jeff Bezos at the retailer’s helm.A year into the throes of the COVID-19 pandemic, Amazon’s financial luster is fading slightly. When brick-and-mortar stores closed, Amazon posted record profits, drew more than 200 million Prime loyalty subscribers, and recruited over 500,000 workers to keep up with surging deman","content":"<p>(Reuters) -Amazon.com Inc on Thursday said sales growth would decelerate in the third quarter as customers leave their homes more, a slow start to the reign of CEO Andy Jassy after 27 years with Jeff Bezos at the retailer’s helm.</p>\n<p>Shares fell 7% in after-hours trade.</p>\n<p>A year into the throes of the COVID-19 pandemic, Amazon’s financial luster is fading slightly. When brick-and-mortar stores closed, Amazon posted record profits, drew more than 200 million Prime loyalty subscribers, and recruited over 500,000 workers to keep up with surging demand.</p>\n<p>Now, the company is facing the tough task of climbing higher still. While revenue grew 44% in the first quarter of this year, that figure dropped to 27% for the period ended June 30. Sales may only grow as much as 16% in the third quarter, Amazon said.</p>\n<p>Brian Olsavsky, Amazon’s chief financial officer, attributed this to a difficult comparison to last year, when consumers stayed more indoors and relied on e-commerce for their everyday needs. In the United States and Europe, customers are now out and about.</p>\n<p>They are “doing other things besides shopping,” he said.</p>\n<p>Amazon expects this lower growth to continue for the next few quarters, Olsavsky told reporters.</p>\n<p>The outlook comes just after Jassy inherited Amazon’s top job on July 5, which has never been bigger or more complex. Last quarter Amazon announced a deal to buy the film studio MGM for $8.5 billion, expanding in Hollywood at the same time as it is running a grocery chain, building a healthcare business and facing scrutiny from regulators worldwide.</p>\n<p>Olsavsky said the company hopes COVID-19 will subside and that the economy will continue to bounce back, but it will require masks for vaccinated staff if that becomes necessary.</p>\n<p>While other tech companies this week such as Alphabet Inc and Facebook Inc announced they will require vaccines for workers returning to their offices, Amazon has yet to announce a vaccine requirement for employees in its offices -- or warehouse workers and drivers.</p>\n<p>Amazon has grappled with workplace tumult in recent months, including staff protests over pandemic safety precautions and a high-profile, failed unionization bid in a facility in Bessemer, Alabama.</p>\n<p>Brian Yarbrough, an analyst with Edward Jones, said it was “not feasible” for Amazon to maintain its growth.</p>\n<p>“No doubt, online retail will probably slow down to that growth somewhere in the 10%-12% range. It’s still phenomenal growth when you think of the sheer size of the business,” he said. “Obviously the pandemic helped them, but they’re not going to be able to grow that rapidly on top of those numbers.”</p>\n<p>LABOR SHORTAGE</p>\n<p>Revenue was $113 billion for the second quarter, shy of analysts’ average estimate of $115 billion.</p>\n<p>The world’s biggest online retailer had moved its annual marketing blitz, Prime Day, to June this year, hoping to peddle more goods before shoppers left town on summer vacations. While it said the event was the biggest two-day sales period ever for merchants on its platform, analysts have witnessed signs of slowing demand.</p>\n<p>North America, Amazon’s largest market, saw sales increase only 22% in the second quarter, versus 43% in the same period a year earlier.</p>\n<p>Amazon Web Services was a bright spot, however. The cloud computing division that Jassy formerly ran grew revenue 37% to $14.8 billion, ahead of estimates of more than $14.1 billion. Among the deals it inked in the just-ended quarter was an agreement with Canada’s BMO Financial Group.</p>\n<p>Profit rose 48% to $7.8 billion, the second-largest quarterly result Amazon ever announced.</p>\n<p>Still, enormous challenges come with Amazon’s size.</p>\n<p>Costs continue to rise, not just from the $200 million in extra stock Amazon plans to pay Jassy over the next 10 years. The company has offered an average $17 in hourly wages - more than double the U.S. minimum - plus signing bonuses to attract 75,000 workers during a labor shortage.</p>\n<p>It has said it planned to hike pay for over half a million employees, costing more than $1 billion, and like other companies, it is facing clogged ports and other disruptions to the transportation supply chain.</p>\n<p>The No.2 U.S. employer this winter became a rallying point for organized labor, which wanted to form Amazon’s first U.S. union and inspire similar efforts across the country. Amazon is awaiting a decision on whether a U.S. National Labor Board director will overturn its landslide victory in the Bessemer, Alabama union election and call for a rerun.</p>\n<p>Following the April vote count, Bezos said he aimed to make Amazon a better place to work. It is unclear how he will govern from the sidelines in the role of executive chair of Amazon’s board.</p>\n<p>Amazon said it expects operating income for the current quarter to be between $2.5 billion and $6.0 billion, which assumes $1 billion in costs related to COVID-19.</p>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Amazon sales growth slows in tame start to Jassy's tenure as CEO</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nAmazon sales growth slows in tame start to Jassy's tenure as CEO\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-07-30 07:06 GMT+8 <a href=https://www.reuters.com/article/amazoncom-results/update-4-amazon-sales-growth-slows-in-tame-start-to-jassys-tenure-as-ceo-idUSL4N2P53XQ><strong>Reuters</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>(Reuters) -Amazon.com Inc on Thursday said sales growth would decelerate in the third quarter as customers leave their homes more, a slow start to the reign of CEO Andy Jassy after 27 years with Jeff ...</p>\n\n<a href=\"https://www.reuters.com/article/amazoncom-results/update-4-amazon-sales-growth-slows-in-tame-start-to-jassys-tenure-as-ceo-idUSL4N2P53XQ\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"AMZN":"亚马逊"},"source_url":"https://www.reuters.com/article/amazoncom-results/update-4-amazon-sales-growth-slows-in-tame-start-to-jassys-tenure-as-ceo-idUSL4N2P53XQ","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1105519179","content_text":"(Reuters) -Amazon.com Inc on Thursday said sales growth would decelerate in the third quarter as customers leave their homes more, a slow start to the reign of CEO Andy Jassy after 27 years with Jeff Bezos at the retailer’s helm.\nShares fell 7% in after-hours trade.\nA year into the throes of the COVID-19 pandemic, Amazon’s financial luster is fading slightly. When brick-and-mortar stores closed, Amazon posted record profits, drew more than 200 million Prime loyalty subscribers, and recruited over 500,000 workers to keep up with surging demand.\nNow, the company is facing the tough task of climbing higher still. While revenue grew 44% in the first quarter of this year, that figure dropped to 27% for the period ended June 30. Sales may only grow as much as 16% in the third quarter, Amazon said.\nBrian Olsavsky, Amazon’s chief financial officer, attributed this to a difficult comparison to last year, when consumers stayed more indoors and relied on e-commerce for their everyday needs. In the United States and Europe, customers are now out and about.\nThey are “doing other things besides shopping,” he said.\nAmazon expects this lower growth to continue for the next few quarters, Olsavsky told reporters.\nThe outlook comes just after Jassy inherited Amazon’s top job on July 5, which has never been bigger or more complex. Last quarter Amazon announced a deal to buy the film studio MGM for $8.5 billion, expanding in Hollywood at the same time as it is running a grocery chain, building a healthcare business and facing scrutiny from regulators worldwide.\nOlsavsky said the company hopes COVID-19 will subside and that the economy will continue to bounce back, but it will require masks for vaccinated staff if that becomes necessary.\nWhile other tech companies this week such as Alphabet Inc and Facebook Inc announced they will require vaccines for workers returning to their offices, Amazon has yet to announce a vaccine requirement for employees in its offices -- or warehouse workers and drivers.\nAmazon has grappled with workplace tumult in recent months, including staff protests over pandemic safety precautions and a high-profile, failed unionization bid in a facility in Bessemer, Alabama.\nBrian Yarbrough, an analyst with Edward Jones, said it was “not feasible” for Amazon to maintain its growth.\n“No doubt, online retail will probably slow down to that growth somewhere in the 10%-12% range. It’s still phenomenal growth when you think of the sheer size of the business,” he said. “Obviously the pandemic helped them, but they’re not going to be able to grow that rapidly on top of those numbers.”\nLABOR SHORTAGE\nRevenue was $113 billion for the second quarter, shy of analysts’ average estimate of $115 billion.\nThe world’s biggest online retailer had moved its annual marketing blitz, Prime Day, to June this year, hoping to peddle more goods before shoppers left town on summer vacations. While it said the event was the biggest two-day sales period ever for merchants on its platform, analysts have witnessed signs of slowing demand.\nNorth America, Amazon’s largest market, saw sales increase only 22% in the second quarter, versus 43% in the same period a year earlier.\nAmazon Web Services was a bright spot, however. The cloud computing division that Jassy formerly ran grew revenue 37% to $14.8 billion, ahead of estimates of more than $14.1 billion. Among the deals it inked in the just-ended quarter was an agreement with Canada’s BMO Financial Group.\nProfit rose 48% to $7.8 billion, the second-largest quarterly result Amazon ever announced.\nStill, enormous challenges come with Amazon’s size.\nCosts continue to rise, not just from the $200 million in extra stock Amazon plans to pay Jassy over the next 10 years. The company has offered an average $17 in hourly wages - more than double the U.S. minimum - plus signing bonuses to attract 75,000 workers during a labor shortage.\nIt has said it planned to hike pay for over half a million employees, costing more than $1 billion, and like other companies, it is facing clogged ports and other disruptions to the transportation supply chain.\nThe No.2 U.S. employer this winter became a rallying point for organized labor, which wanted to form Amazon’s first U.S. union and inspire similar efforts across the country. Amazon is awaiting a decision on whether a U.S. National Labor Board director will overturn its landslide victory in the Bessemer, Alabama union election and call for a rerun.\nFollowing the April vote count, Bezos said he aimed to make Amazon a better place to work. It is unclear how he will govern from the sidelines in the role of executive chair of Amazon’s board.\nAmazon said it expects operating income for the current quarter to be between $2.5 billion and $6.0 billion, which assumes $1 billion in costs related to COVID-19.","news_type":1},"isVote":1,"tweetType":1,"viewCount":169,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":123803398,"gmtCreate":1624414132814,"gmtModify":1631891044190,"author":{"id":"3583646104988043","authorId":"3583646104988043","name":"ShawnHeng","avatar":"https://static.tigerbbs.com/72e8cfcb05b06fcd153a93daf9b7196a","crmLevel":2,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"3583646104988043","idStr":"3583646104988043"},"themes":[],"htmlText":"👍","listText":"👍","text":"👍","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":2,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/123803398","repostId":"2145061761","repostType":4,"repost":{"id":"2145061761","kind":"news","pubTimestamp":1624411200,"share":"https://www.laohu8.com/m/news/2145061761?lang=&edition=full","pubTime":"2021-06-23 09:20","market":"us","language":"en","title":"Second Sight Medical Products Announces Pricing of Public Offering","url":"https://stock-news.laohu8.com/highlight/detail?id=2145061761","media":"Business Wire","summary":"LOS ANGELES, June 23, 2021--(BUSINESS WIRE)--Second Sight Medical Products, Inc. (NASDAQ: EYES) (\"Se","content":"<p><b>LOS ANGELES, June 23, 2021</b>--(BUSINESS WIRE)--<a href=\"https://laohu8.com/S/EYES\">Second Sight Medical Products</a>, Inc. (NASDAQ: EYES) (\"Second Sight\" or the \"Company\"), a leading developer of implantable visual prosthetics that are intended to create an artificial form of useful vision for blind individuals, today announced the pricing of its underwritten public offering of 10,000,000 shares of its common stock at a public offering price of $5.00 per share, for gross proceeds of $50,000,000, before deducting underwriting discounts, commissions and other offering expenses. In addition, the Company has granted the underwriters a 45-day option to purchase up to an additional 1,500,000 shares of common stock, solely to cover over-allotments. All of the shares of common stock are being offered by the Company.</p>\n<p>The offering is expected to close on June 25, 2021, subject to satisfaction of customary closing conditions.</p>\n<p>ThinkEquity, a division of Fordham Financial Management, Inc., is acting as sole book-running manager for the offering.</p>\n<p>The Company intends to use the net proceeds from the offering primarily for development of the Orion device and general corporate purposes.</p>\n<p>The securities will be offered and sold pursuant to a shelf registration statement on Form S-3 (File No. 333-256904), including a base prospectus, filed with the U.S. Securities and Exchange Commission (the \"SEC\") on June 8, 2021 and declared effective on June 14, 2021. The offering will be made only by means of a written prospectus. A preliminary prospectus supplement and accompanying prospectus describing the terms of the offering has been filed with the SEC on its website at www.sec.gov. Copies of the preliminary prospectus supplement and the accompanying prospectus relating to the offering may also be obtained from the offices of ThinkEquity, a division of Fordham Financial Management, Inc., 17 State Street, 22nd Floor, New York, New York 10004, by telephone at (877) 436-3673 or by email at prospectus@think-equity.com. Before investing in this offering, interested parties should read in their entirety the preliminary prospectus supplement and the accompanying prospectus and the other documents that the Company has filed with the SEC that are incorporated by reference in such preliminary prospectus supplement and the accompanying prospectus, which provide more information about the Company and such offering.</p>\n<p>This press release shall not constitute an offer to sell or a solicitation of an offer to buy, nor shall there be any sale of these securities in any state or jurisdiction in which such an offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction.</p>\n<p><b>About the Orion Visual Cortical Prosthesis System</b></p>\n<p>Leveraging Second Sight’s 20 years of experience in neuromodulation for vision, the Orion Visual Cortical Prosthesis System (Orion) is an implanted cortical stimulation device intended to provide useful artificial vision to individuals who are blind due to a wide range of causes, including glaucoma, diabetic retinopathy, optic nerve injury or disease, and eye injury. Orion is intended to convert images captured by a miniature video camera mounted on glasses into a series of small electrical pulses. The device is designed to bypass diseased or injured eye anatomy and to transmit these electrical pulses wirelessly to an array of electrodes implanted on the surface of the brain’s visual cortex, where it is intended to provide the perception of patterns of light. A six-subject early feasibility study of the Orion is currently underway at the Ronald Reagan UCLA Medical Center in Los Angeles and the Baylor College of Medicine in Houston. No peer-reviewed data is available yet for the Orion system.</p>\n<p><b>About Second Sight Medical Products, Inc.</b></p>\n<p>Second Sight Medical Products, Inc. (Nasdaq: EYES) develops implantable visual prosthetics that are intended to deliver useful artificial vision to blind individuals. A recognized global leader in neuromodulation devices for blindness, the Company is committed to developing new technologies to treat the broadest population of sight-impaired individuals. The Company’s headquarters are in Los Angeles, California. More information is available at https://secondsight.com/.</p>","source":"yahoofinance","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Second Sight Medical Products Announces Pricing of Public Offering</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nSecond Sight Medical Products Announces Pricing of Public Offering\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-06-23 09:20 GMT+8 <a href=https://finance.yahoo.com/news/second-sight-medical-products-announces-005900674.html><strong>Business Wire</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>LOS ANGELES, June 23, 2021--(BUSINESS WIRE)--Second Sight Medical Products, Inc. (NASDAQ: EYES) (\"Second Sight\" or the \"Company\"), a leading developer of implantable visual prosthetics that are ...</p>\n\n<a href=\"https://finance.yahoo.com/news/second-sight-medical-products-announces-005900674.html\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{},"source_url":"https://finance.yahoo.com/news/second-sight-medical-products-announces-005900674.html","is_english":true,"share_image_url":"https://static.laohu8.com/5f26f4a48f9cb3e29be4d71d3ba8c038","article_id":"2145061761","content_text":"LOS ANGELES, June 23, 2021--(BUSINESS WIRE)--Second Sight Medical Products, Inc. (NASDAQ: EYES) (\"Second Sight\" or the \"Company\"), a leading developer of implantable visual prosthetics that are intended to create an artificial form of useful vision for blind individuals, today announced the pricing of its underwritten public offering of 10,000,000 shares of its common stock at a public offering price of $5.00 per share, for gross proceeds of $50,000,000, before deducting underwriting discounts, commissions and other offering expenses. In addition, the Company has granted the underwriters a 45-day option to purchase up to an additional 1,500,000 shares of common stock, solely to cover over-allotments. All of the shares of common stock are being offered by the Company.\nThe offering is expected to close on June 25, 2021, subject to satisfaction of customary closing conditions.\nThinkEquity, a division of Fordham Financial Management, Inc., is acting as sole book-running manager for the offering.\nThe Company intends to use the net proceeds from the offering primarily for development of the Orion device and general corporate purposes.\nThe securities will be offered and sold pursuant to a shelf registration statement on Form S-3 (File No. 333-256904), including a base prospectus, filed with the U.S. Securities and Exchange Commission (the \"SEC\") on June 8, 2021 and declared effective on June 14, 2021. The offering will be made only by means of a written prospectus. A preliminary prospectus supplement and accompanying prospectus describing the terms of the offering has been filed with the SEC on its website at www.sec.gov. Copies of the preliminary prospectus supplement and the accompanying prospectus relating to the offering may also be obtained from the offices of ThinkEquity, a division of Fordham Financial Management, Inc., 17 State Street, 22nd Floor, New York, New York 10004, by telephone at (877) 436-3673 or by email at prospectus@think-equity.com. Before investing in this offering, interested parties should read in their entirety the preliminary prospectus supplement and the accompanying prospectus and the other documents that the Company has filed with the SEC that are incorporated by reference in such preliminary prospectus supplement and the accompanying prospectus, which provide more information about the Company and such offering.\nThis press release shall not constitute an offer to sell or a solicitation of an offer to buy, nor shall there be any sale of these securities in any state or jurisdiction in which such an offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction.\nAbout the Orion Visual Cortical Prosthesis System\nLeveraging Second Sight’s 20 years of experience in neuromodulation for vision, the Orion Visual Cortical Prosthesis System (Orion) is an implanted cortical stimulation device intended to provide useful artificial vision to individuals who are blind due to a wide range of causes, including glaucoma, diabetic retinopathy, optic nerve injury or disease, and eye injury. Orion is intended to convert images captured by a miniature video camera mounted on glasses into a series of small electrical pulses. The device is designed to bypass diseased or injured eye anatomy and to transmit these electrical pulses wirelessly to an array of electrodes implanted on the surface of the brain’s visual cortex, where it is intended to provide the perception of patterns of light. A six-subject early feasibility study of the Orion is currently underway at the Ronald Reagan UCLA Medical Center in Los Angeles and the Baylor College of Medicine in Houston. No peer-reviewed data is available yet for the Orion system.\nAbout Second Sight Medical Products, Inc.\nSecond Sight Medical Products, Inc. (Nasdaq: EYES) develops implantable visual prosthetics that are intended to deliver useful artificial vision to blind individuals. A recognized global leader in neuromodulation devices for blindness, the Company is committed to developing new technologies to treat the broadest population of sight-impaired individuals. The Company’s headquarters are in Los Angeles, California. More information is available at https://secondsight.com/.","news_type":1},"isVote":1,"tweetType":1,"viewCount":325,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":176500112,"gmtCreate":1626904165436,"gmtModify":1631891044187,"author":{"id":"3583646104988043","authorId":"3583646104988043","name":"ShawnHeng","avatar":"https://static.tigerbbs.com/72e8cfcb05b06fcd153a93daf9b7196a","crmLevel":2,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"3583646104988043","idStr":"3583646104988043"},"themes":[],"htmlText":"👍","listText":"👍","text":"👍","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/176500112","repostId":"1183334651","repostType":2,"repost":{"id":"1183334651","kind":"news","weMediaInfo":{"introduction":"Providing stock market headlines, business news, financials and earnings ","home_visible":1,"media_name":"Tiger Newspress","id":"1079075236","head_image":"https://static.tigerbbs.com/8274c5b9d4c2852bfb1c4d6ce16c68ba"},"pubTimestamp":1626444637,"share":"https://www.laohu8.com/m/news/1183334651?lang=&edition=full","pubTime":"2021-07-16 22:10","market":"us","language":"en","title":"Exela Technologies soars 10% amid listing of option contracts on NYSE Arca","url":"https://stock-news.laohu8.com/highlight/detail?id=1183334651","media":"Tiger Newspress","summary":"Exela Technologies rises 10% in early trading while the company announced that NYSE Arca launched op","content":"<p>Exela Technologies rises 10% in early trading while the company announced that NYSE Arca launched options trading in XELA.</p>\n<p><img src=\"https://static.tigerbbs.com/94f4a006aac82b04b4e1ee25a23b79b6\" tg-width=\"1276\" tg-height=\"597\" referrerpolicy=\"no-referrer\"></p>\n<p>Trading is expected to begin July 16.</p>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Exela Technologies soars 10% amid listing of option contracts on NYSE Arca</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nExela Technologies soars 10% amid listing of option contracts on NYSE Arca\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1079075236\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/8274c5b9d4c2852bfb1c4d6ce16c68ba);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Tiger Newspress </p>\n<p class=\"h-time\">2021-07-16 22:10</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>Exela Technologies rises 10% in early trading while the company announced that NYSE Arca launched options trading in XELA.</p>\n<p><img src=\"https://static.tigerbbs.com/94f4a006aac82b04b4e1ee25a23b79b6\" tg-width=\"1276\" tg-height=\"597\" referrerpolicy=\"no-referrer\"></p>\n<p>Trading is expected to begin July 16.</p>\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"XELA":"Exela Technologies, Inc."},"is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1183334651","content_text":"Exela Technologies rises 10% in early trading while the company announced that NYSE Arca launched options trading in XELA.\n\nTrading is expected to begin July 16.","news_type":1},"isVote":1,"tweetType":1,"viewCount":212,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0}],"lives":[]}
